PDE5A抗体

+ +

•  

   

     Gel: 6%SDS-PAGE, Lysate: 40 μg, Lane: Mouse skeletal muscle tissue lysate, Primary antibody: P05149(PDE5A Antibody) at dilution 1/600, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 2 minutes    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P05149(PDE5A Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P05149(PDE5A Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The PDE5A antibody is a crucial tool in biomedical research, targeting phosphodiesterase type 5A (PDE5A), an enzyme that hydrolyzes cyclic guanosine monophosphate (cGMP) to regulate cellular signaling. PDE5A is widely expressed in vascular smooth muscle, platelets, and the corpus cavernosum, playing a key role in cardiovascular function and erectile physiology. Its inhibition by drugs like sildenafil (Viagra) underscores its therapeutic relevance. Researchers use PDE5A antibodies to study the enzyme's expression, localization, and activity in tissues or cells, aiding investigations into conditions such as pulmonary hypertension, erectile dysfunction, and cancer, where PDE5A dysregulation is implicated.

These antibodies are typically validated for applications like Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and enzyme-linked immunosorbent assays (ELISA). Specificity is ensured through knockout controls or peptide blocking experiments. Monoclonal antibodies offer high specificity, while polyclonal versions may detect multiple isoforms (PDE5A1. PDE5A2). Host species (rabbit, mouse) and clonality are selected based on experimental needs.

Commercial PDE5A antibodies are often accompanied by validation data, ensuring reproducibility in studies exploring PDE5A's role in cGMP-dependent pathways, smooth muscle relaxation, or drug resistance. Their utility extends to biomarker discovery and therapeutic target validation, bridging basic research and clinical applications. Proper controls and optimized protocols are critical to avoid cross-reactivity with other PDE family members.